HONG KONG, Jan. 22, 2025 /PRNewswire/ — On January 22, 2025, Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. (“Sichuan Kelun”) for their collaboration on the development of tagitanlimab, an innovative humanized monoclonal antibody targeting PD-L1, following its recent marketing approval by China’s National Medical Products Administration.
In 2014, Akeso signed a cooperation agreement with Sichuan Kelun for the development of tagitanlimab. Under the terms of the agreement, Akeso will receive royalties from the commercial sales of tagitanlimab in addition to the development payment.
Tagitanlimab marks Akeso’s second oncology product to yield commercial royalties, following pucotenlimab, a PD-1 monoclonal antibody developed in collaboration with Lepu Biopharma in 2016.
Dr. Yu Xia, founder, chairwoman, president, and CEO of Akeso, said: “Congratulations to our partners. We are thrilled about continuously successful approval of our innovative products, and truly anticipate their outstanding commercialization performance. This achievement highlights Akeso’s strong R&D capabilities and our commitment to innovation. Since its inception, Akeso has established multiple external collaborations, including ivonescimab with Summit Therapeutics, quavonlimab with Merck and pucotenlimab with Lepu Biopharma. These partnerships not only benefit patients but also deliver significant returns for both Akeso and our collaborators. Looking ahead, Akeso will continue to pursue a diversified strategy for new drug development, leveraging global resources to drive the high-quality commercialization of our independently developed innovative therapeutics.”
ข่าวที่เกี่ยวข้อง
- Binance Blockchain Week Bangkok 2026 Unveils First Wave of Speakers, Spotlighting the Convergence of Traditional Finance and Digital Assets
- Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of Obesity
- Hitachi Energy recognized as a Leader in the 2026 IDC MarketScape for worldwide advanced distribution management systems
- SEEKINK Showcases Innovative E-Paper Applications and OEM/ODM Solutions at Electronica 2026
